A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 6
- 主要终点
- Tumor response
研究概览
简要总结
DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.
详细描述
The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.
The Food Effect (FE) part of this study is to determine the effect of food on the PK of DS-6051a following administration of a single oral dose of DS-6051b. The safety and tolerability of DS-6051b administered with or without food will also be assessed.
After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available
- •Part 1 Dose Escalation subjects must meet 1 of the following criteria:
- •Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
- •Neuroendocrine tumors
- •Solid tumors with tumor-induced pain
- •Part 2 Dose Expansion subjects must meet 1 of the following criteria:
- •NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
- •k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement
- •Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
- •Pulmonary LCNEC;
- •Male or female ≥18 years of age
- •Eastern Cooperative Oncology Group performance status 0 to 1
- •Adequate organ function
- •Adequate blood clotting function
- •Women of childbearing potential must have a negative pregnancy test
- •Willingness to provide archival tumor samples
- •Other inclusion criteria may apply
排除标准
- •Hematological malignancies
- •Known positive HIV infection, or active hepatitis B or C infection
- •Comorbidity that would interfere with therapy
- •Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
- •Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor
- •History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4
- •Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
- •Unresolved toxicities from previous anticancer therapy
- •Systemic treatment with anticancer therapy within 3 weeks before study drug treatment
- •Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
- •Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment
- •Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein
- •Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption
- •QTcF values higher than 450 ms at screening
- •Breastfeeding
- •Other exclusion criteria may apply
研究组 & 干预措施
DS-6051b
DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
干预措施: DS6051b (Drug)
结局指标
主要结局
Tumor response
时间窗: up to 2 years
Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Part 1: Number of participants with dose-limiting toxicities
时间窗: within 21 days following the first dose of treatment
次要结局
- Change from baseline in QTc interval(within 2 years)
- Maximum concentration (Cmax) for DS-6051a(At Days 1 and 15 of Cycle 1 (21 days))
- Time to maximum concentration (Tmax) for DS-6051a(At Days 1 and 15 of Cycle 1 (21 days))
- Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a(At Days 1 and 15 of Cycle 1 (21 days))